Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

119.47 -1.29 (-1.07%)
Streaming Delayed Price Updated: 12:28 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biontech Se ADR

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
65 66 Next >
The 7 Best Pharma Stocks to Buy Now
Investors searching for gains in the current market storm should consider taking a position in some of the best pharma stocks. 
Via InvestorPlace
Got $2,000? 2 Fantastic Stocks to Buy No Matter What the Market Does Next
These stocks both have non-cyclical businesses that can drive growth in a wide variety of markets. 
Via The Motley Fool
BioNTech SE (BNTX) Q3 2022 Earnings Call Transcript
BNTX earnings call for the period ending September 30, 2022. 
Via The Motley Fool
BioNTech Takes A Hit Despite Doubling Profit Views, Raising 2022 Outlook
BioNTech doubled profit expectations in the third quarter and raised its outlook. 
Via Investor's Business Daily
Meta Goes Twitter Way With Layoffs, Twitter Might Want Some People Back After Firing Them, Coal Miners Terminate $6B Combination Discussions: Top Stories Monday, Nov. 07
Wall Street Journal 
Via Benzinga
BioNTech Posts About 50% Drop In Q3 Sales and Profits Amid Falling Demand For COVID-19 Shots
Via Benzinga
Risk Appetites Survive China Keeping Zero COVID Policy
Chinese officials denied plans to end the zero-COVID policy and after a brief wobble, risk assets have traded better. Asia Pacific equities rallied, led by Hong Kong and mainland stocks that trade in... 
Via Talk Markets
Recap: BioNTech Q3 Earnings
BioNTech (NASDAQ:BNTX) reported its Q3 earnings results on Monday, November 7, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Earnings BioNTech beat estimated earnings by... 
Via Benzinga
BioNTech Announces Third Quarter 2022 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
Week in Review: CBC Plans $137 Million Shanghai Biopharma Complex
Deals, financings, trials and approvals in Chinese biotech/biopharma this week. 
Via Talk Markets
Did Vaccine Stocks Just Get Their Last Boost?
Some positive news sent their share prices higher, but biotech companies will need to find other ways to make money. 
Via The Motley Fool
This Key Piece Of News Could Sparked BioNTech, Moderna — And Could Stoke Demand For Covid Boosters
Pfizer and BioNTech tested their updated Covid booster against the original shot. 
Via Investor's Business Daily
BioNTech's COVID-19 Vaccine Becomes First Foreign Shot To Be Available In Chinese Market
German Chancellor Olaf Scholz agreed to allow expatriates in China to use BioNTech SE (NASDAQ: BNTX) made COVID-19 vaccine. BioNTech would be the first non-Chinese coronavirus vaccine in China, as... 
Via Benzinga
Pfizer/BioNTech Updated Omicron Adapted COVID-19 Vaccine Shows 4-Fold Higher Neutralizing Activity
Via Benzinga
BioNTech Shares Up On Hope For Combined Flu, Covid Shot
The shot will combine Pfizer's quadrivalent flu shot with the bivalent Covid booster. 
Via Investor's Business Daily
Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine
From BioNTech SE
Via GlobeNewswire
Pfizer, BioNTech Launch Omicron-Adapted COVID Shot-Flu Combination Vaccine Study
Via Benzinga
Why Inovio Pharmaceuticals Stock Zoomed Nearly 6% Higher Today
The biotech is ceasing its internally funded efforts to develop a heterologous coronavirus booster. 
Via The Motley Fool
Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
A New BioTech Research Race Is Focused On Improving Life For MS Patients
When the world is focused on a global pandemic no one saw coming four years ago, the attention given to escalating diseases with no known cure can be hidden from the public consciousness. This is... 
Via Benzinga
Is BioNTech a Good Long-Term Buy?
BioNTech has a burgeoning oncology portfolio up its sleeve. 
Via The Motley Fool
Are Pfizer and Moderna Stocks Buys With a Potential COVID Surge Coming?
There's still considerable near-term uncertainty for both of these vaccine makers. 
Via The Motley Fool
JP Morgan Maintains Neutral Rating for BioNTech: Here's What You Need To Know
JP Morgan has decided to maintain its Neutral rating of BioNTech (NASDAQ:BNTX) and lower its price target from $183.00 to $132.00. Shares of BioNTech are trading down 0.68% over the last 24 hours, at... 
Via Benzinga
BioNTech to Report Third Quarter 2022 Financial Results and Operational Update on November 7, 2022
From BioNTech SE
Via GlobeNewswire
Moderna, Amazon, Tesla, And Other Big Gainers From Friday
U.S. stocks closed higher on Friday, with the Dow Jones gaining around 750 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Why Huntington Bancshares Shares Surged Around 10%; Here Are 72 Biggest Movers From Friday
Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) jumped 89.3% to close at $58.92 on Friday. 
Via Benzinga
Why Novavax Stock Rose 12.57% on Friday
Investors did an about-face after the stock slumped earlier in the week. 
Via The Motley Fool
Why Are Vaccine Stocks MRNA, PFE, BNTX, NVAX Up Today?
Vaccine stocks are flying higher on Friday on word that Pfizer will quadruple the price of its Covid-19 vaccine. Will others follow suit? 
Via InvestorPlace
Why Boston Beer Shares Are Trading Higher? Here Are 52 Stocks Moving In Friday's Mid-Day Session
Gainers Altamira Therapeutics Ltd. (NASDAQ: CYTO) surged 67% to $0.5484 after the company announced divestiture of its inner ear development assets. 
Via Benzinga
Twitter Rebuffs Elon Musk Layoff Plans Report, Toyota Cuts 2023's Production Target, Vaccine Makers Expect 3x Price Increase In COVID-19 Shot: Top Stories Friday, Oct. 21
Bloomberg 
Via Benzinga
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.